Complete response letter for GSK/XenoPort's Horizant over cancer concern
This article was originally published in Scrip
Executive Summary
The US FDA has issued GlaxoSmithKline and XenoPort a complete response letter for their non-dopaminergic restless legs syndrome (RLS) therapy, Horizant (gabapentin enacarbil extended-release, previously known as Solzira).